Bristol Myers Squibb stock enters a week of pipeline catalysts

Bristol Myers Squibb is entering November with its late-stage pipeline at the center of the investment case. In the company's October 29 earnings call, management said it expects Phase 3 data for milvexian in secondary stroke prevention and Sotyktu in lupus before the end of 2026. The Bristol Myers Squibb earnings-call transcript published by Yahoo Finance also points to further clinical milestones in 2027.

Bristol Myers Squibb stock traded at 56.05 euros on Lang & Schwarz at 13:02 CET on Tuesday, November 3, 2026.

Late-stage data set the agenda

Chief Executive Chris Boerner said the company had seen several positive registrational readouts and regulatory approvals in recent months. Management expects more data to clarify the next wave of potential launches, keeping clinical execution in focus as investors assess the company's growth beyond established products.

The near-term pipeline calendar includes milvexian, a Factor XIa inhibitor being developed with Johnson & Johnson, and Sotyktu, which is being tested in lupus. The company also expects to present open-label Alzheimer's disease psychosis data from the ADEPT-1 study and the ADEPT-3 long-term extension at the Clinical Trials on Alzheimer's Disease conference in Boston in November.

Management characterized the Cobenfy data as encouraging while noting that randomized controlled studies still have to report. The company expects a potential interim analysis for ADEPT-1 later this year, while top-line results across the broader ADEPT program are expected throughout 2027. Additional 2027 milestones include milvexian data in atrial fibrillation, bipolar I data from the Cobenfy BALSAM studies and the first registrational data for golcadomide in high-risk first-line large B-cell lymphoma.

Growth portfolio offsets patent pressure

The pipeline focus comes alongside solid commercial momentum. Third-quarter revenue rose 7 percent year over year to approximately 13.1 billion US dollars, while growth-portfolio revenue increased 12 percent to 7.7 billion US dollars, according to management. QVANTIG revenue reached 334 million US dollars, up 28 percent sequentially, and BREYANZI revenue rose 48 percent to 526 million US dollars.

ELIQUIS revenue increased 26 percent to approximately 4.7 billion US dollars in the quarter, helped by pricing, demand and market-share gains. Management nevertheless expects European loss of exclusivity to affect fourth-quarter sales and has indicated a 1.5 billion to 2 billion US dollar step-down for 2027. That makes delivery from newer products and the pipeline increasingly important for the company's medium-term growth profile.

Bristol Myers Squibb said its growth portfolio now comprises eight medicines with annualized sales above 1 billion US dollars based on third-quarter performance. The company also raised its full-year revenue outlook, while its 2026 non-GAAP earnings-per-share range stands at 6.35 to 6.55 US dollars after a 0.58 US dollar per-share impact from acquired in-process research and development and licensing income.

Bristol Myers Squibb stock overview

• Company: Bristol Myers Squibb
• ISIN: US1101221083
• Ticker: BMY
• Quote: 56.05 euros on Lang & Schwarz at 13:02 CET on Tuesday, November 3, 2026

Investors can follow the real-time quote of Bristol Myers Squibb stock while the clinical calendar develops.

The S&P 500 is the relevant US market backdrop for Bristol Myers Squibb, with current market reports available for the index.

More news and analyses on Bristol Myers Squibb stock will track the next pipeline readouts and the company's response to upcoming exclusivity changes.